Abstract
Recent advanced high-throughput sequencing technologies have offered insights into the molecular landscape of acute myeloid leukemia (AML), revealing its genetic heterogeneity. As recurrent alterations should be related to the molecular pathogenesis of AML, assessing the mutation profile of each patient would contribute to the precise molecular diagnosis, precise risk stratification, and appropriate treatment decisions. In fact, the most recent WHO classification and clinical guidelines for AML are categorized by genetic alterations. In addition, serial monitoring of genetic markers could be useful to detect minimal residual disease (MRD) at the time of complete remission as well as clonal changes during the disease course. Because large databases of matched clinical genomics data are needed to use complicated genomic data for clinical decision making, we have been constructing an integrated database of hematological malignancies (knonc) supported by the AMED since 2016. Precision medicine for AML based on genetic information will provide optimal target drugs and useful information for the enhancement of clinical outcome.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
